Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.90
MYOS's Cash to Debt is ranked higher than
76% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MYOS: 2.90 )
MYOS' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 2.9

Equity to Asset 0.87
MYOS's Equity to Asset is ranked higher than
92% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MYOS: 0.87 )
MYOS' s 10-Year Equity to Asset Range
Min: 0.17   Max: 0.96
Current: 0.87

0.17
0.96
Interest Coverage No Debt
MYOS's Interest Coverage is ranked higher than
76% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. MYOS: No Debt )
MYOS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 11.44
M-Score: 0.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -105.70
MYOS's Operating margin (%) is ranked higher than
50% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. MYOS: -105.70 )
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.42   Max: -128.6
Current: -105.7

-4642.42
-128.6
Net-margin (%) -105.65
MYOS's Net-margin (%) is ranked higher than
50% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MYOS: -105.65 )
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.54   Max: -128.48
Current: -105.65

-5653.54
-128.48
ROE (%) -87.95
MYOS's ROE (%) is ranked lower than
51% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. MYOS: -87.95 )
MYOS' s 10-Year ROE (%) Range
Min: -2665.24   Max: -89.39
Current: -87.95

-2665.24
-89.39
ROA (%) -77.60
MYOS's ROA (%) is ranked lower than
53% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. MYOS: -77.60 )
MYOS' s 10-Year ROA (%) Range
Min: -2600   Max: -45
Current: -77.6

-2600
-45
ROC (Joel Greenblatt) (%) -263.60
MYOS's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. MYOS: -263.60 )
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -306400   Max: -739.51
Current: -263.6

-306400
-739.51
EBITDA Growth (%) 357.10
MYOS's EBITDA Growth (%) is ranked higher than
100% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. MYOS: 357.10 )
MYOS' s 10-Year EBITDA Growth (%) Range
Min: -37   Max: 508.7
Current: 357.1

-37
508.7
EPS Growth (%) 358.70
MYOS's EPS Growth (%) is ranked higher than
100% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MYOS: 358.70 )
MYOS' s 10-Year EPS Growth (%) Range
Min: -37   Max: 510
Current: 358.7

-37
510
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.26
MYOS's P/B is ranked higher than
68% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MYOS: 4.26 )
MYOS' s 10-Year P/B Range
Min: 0.04   Max: 8.02
Current: 4.26

0.04
8.02
P/S 4.44
MYOS's P/S is ranked higher than
70% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. MYOS: 4.44 )
MYOS' s 10-Year P/S Range
Min: 0.09   Max: 10
Current: 4.44

0.09
10
EV-to-EBIT -4.64
MYOS's EV-to-EBIT is ranked higher than
51% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. MYOS: -4.64 )
MYOS' s 10-Year EV-to-EBIT Range
Min: -11.4   Max: 1.6
Current: -4.64

-11.4
1.6
Current Ratio 5.32
MYOS's Current Ratio is ranked higher than
87% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MYOS: 5.32 )
MYOS' s 10-Year Current Ratio Range
Min: 0.03   Max: 27.24
Current: 5.32

0.03
27.24
Quick Ratio 2.76
MYOS's Quick Ratio is ranked higher than
79% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MYOS: 2.76 )
MYOS' s 10-Year Quick Ratio Range
Min: 0.03   Max: 26.31
Current: 2.76

0.03
26.31

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.55
MYOS's Price/Net Current Asset Value is ranked higher than
85% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYOS: 13.55 )
MYOS' s 10-Year Price/Net Current Asset Value Range
Min: 0.11   Max: 24.67
Current: 13.55

0.11
24.67
Price/Tangible Book 6.72
MYOS's Price/Tangible Book is ranked higher than
67% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. MYOS: 6.72 )
MYOS' s 10-Year Price/Tangible Book Range
Min: 0.1   Max: 12.23
Current: 6.72

0.1
12.23
Price/Median PS Value 4.19
MYOS's Price/Median PS Value is ranked higher than
55% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. MYOS: 4.19 )
MYOS' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 8
Current: 4.19

0.09
8
Earnings Yield (Greenblatt) -21.60
MYOS's Earnings Yield (Greenblatt) is ranked lower than
51% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYOS: -21.60 )
MYOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 63.7   Max: 74436.8
Current: -21.6

63.7
74436.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
MYOS Corporation Announces $1.81 Million Registered Direct Offering Nov 18 2014 
MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Novemb Nov 11 2014 
MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse Effe Nov 04 2014 
MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropi Oct 30 2014 
MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College Oct 15 2014 

More From Other Websites
Nasdaq stocks posting largest percentage increases Dec 17 2014
MYOS CORP Files SEC form 8-K, Other Events Dec 01 2014
MYOS CORP Financials Nov 21 2014
MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,... Nov 19 2014
MYOS Corporation Announces $1.81 Million Registered Direct Offering Nov 18 2014
MYOS Corporation Announces $1.81 Million Registered Direct Offering Nov 18 2014
10-Q for MYOS Corp. Nov 15 2014
MYOS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Nov 14 2014
MYOS Corporation Reports 2014 Third Quarter Results and Provides Business Update Nov 14 2014
MYOS Corporation Reports 2014 Third Quarter Results and Provides Business Update Nov 14 2014
MYOS CORP Files SEC form 10-Q, Quarterly Report Nov 13 2014
MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on... Nov 11 2014
MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on... Nov 11 2014
MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's™ Lack of Adverse... Nov 04 2014
MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse... Nov 04 2014
MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating... Oct 30 2014
MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating... Oct 30 2014
MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College... Oct 02 2014
MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct... Sep 18 2014
MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on... Sep 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK